CheckMan Stock Market Overview
Trending Stocks
Red List
In Today's Headlines
Chinese smartphone company Xiaomi said Thursday it will sell its first car for far less than Tesla's Model 3, as price wars heat up in China's fiercely competitive electric car market.
Home Depot announced that it's acquiring SRS Distribution — which sells supplies to builders, roofers, landscapers and pool contractors — in a mammoth $18.25 billion deal that includes assumed debt.
SLB is targeting $3 billion in revenue from its new energy business by the end of the decade, with carbon capture and storage expected to play a leading role.
Akamai's performance has been inconsistent, with periods of outperformance and underperformance, mostly due to its business transition. The company is transitioning away from its content delivery business and focusing on security and compute, which are generating incremental revenue. Akamai's security segment has been successful, accounting for a growing share of overall revenue and offsetting declines in the legacy CDN segment. The segment is growing at a 20% CAGR.
Walgreens Boots Alliance (WBA) came out with quarterly earnings of $1.20 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $1.16 per share a year ago.
Shares in chemicals maker Chemours (CC) were down more than 8% in premarket trading Thursday morning as the disclosure of further details relating to an internal accounting probe and a soft current-quarter outlook overshadowed quarterly results that came in ahead of expectations.
With the market favoring riskier assets like cryptocurrency and artificial intelligence stocks, many investors may now look at dividend stocks and other value stocks as overly conservative bets. Sure, many dividend-paying stocks (and companies owning stocks paying dividends) may seem to be overly defensive picks right now.
Blue-chip stocks are associated with a low-beta, stable returns, and passive dividend income for investors. However, not all blue-chip stocks are comparable when it comes to returns over a time-frame.
“Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024.
Strength in end markets and strategic collaborations bode well for Thermo Fisher (TMO).